Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
70 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
OCTAPHARMA BENELUX from Anderlecht, company number BE0862423436, closed financial year 2025 with a result of € 675,474 after tax. For that financial year OCTAPHARMA BENELUX recorded revenue of € 34.4 million and equity of € 7.9 million. Compared with financial year 2024, the result moved from € 659,781 to € 675,474. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 10, 2026.
€ 7.9 million
▲ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 675,474
▲ 2% vs 2024
Profit after tax over the fiscal year.
€ 193,562
▲ 17% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 6.8 million.
People and assets in 2025
3.3
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 618,882
▲ 14% vs 2024
€ 187,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 42,564
▲ 31% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 843,371
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 9 days on average.
€ 332,824
▲ 25% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 27,796,004 | € 24,304,006 | € 24,481,040 | € 34,355,492 | ▲ 40% |
| Profit after taxes | € 743,756 | € 651,131 | € 659,781 | € 675,474 | ▲ 2% |
| Equity | € 5,920,598 | € 6,571,728 | € 7,231,509 | € 7,906,983 | ▲ 9% |
| Total debts | € 8,681,227 | € 3,697,922 | € 3,025,530 | € 10,781,316 | ▲ 256% |
| Cash | € 227,909 | € 183,855 | € 164,780 | € 193,562 | ▲ 17% |
| Retained profit | € 4,820,598 | € 5,471,728 | € 6,131,509 | € 6,806,983 | ▲ 11% |
| Balance sheet total | € 14,601,824 | € 10,269,651 | € 10,257,039 | € 18,688,300 | ▲ 82% |
| Employees (FTE) | 3.3 | 3.7 | 3.2 | 3.3 | ▲ 0.1 |
Key figures of OCTAPHARMA BENELUX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to OCTAPHARMA BENELUX?
What happened at OCTAPHARMA BENELUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Daniel Wyder stepped down as director. NBB
- Stefan Imesch stepped down as director. NBB
- Roger Mächler stepped down as director. NBB
- Norbert Müller stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 675,474 (▲ 2% vs 2024). filed late Source: NBB ↗
- Stefan Imesch became a director. NBB
- Daniel Wyder became a director. NBB
- Roger Mächler became a director. NBB
In short
From € 743,756 profit in 2022 to € 675,474 profit in 2025.
Paid € 960,110 in corporate taxes since 2022.
Best year ever: 2022, with € 743,756 profit.
Pays suppliers within 9 days on average.
A new publication or filing at OCTAPHARMA BENELUX? We notify you, reason included.
Follow OCTAPHARMA BENELUXDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by OCTAPHARMA AG (99.9%) and BIOGAMMA AG (0.1%).
Directors
According to the 2025 annual accounts
Stefan Imesch
Director
since 2024 · until 2029
since 2024 · until 2030
Roger Mächler
Director
since 2024 · until 2029
Norbert Müller
Managing director
since 2024 · until 2029
Shareholders
OCTAPHARMA AG
99.9%
BIOGAMMA AG
0.1%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Lennikse Baan 451
1070 Anderlecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 70 companies are registered at this address.
All companies at this address →FISCHBEIN
€ 13.9 million revenue · 2025
HAIER BENELUX
€ 16.1 million revenue · 2025
PIRELLI TYRES BELUX
€ 3.6 million revenue · 2025
Ferring
€ 21.4 million revenue · 2023
HEALTH DATA MANAGEMENT PARTNERS
€ 1.5 million gross margin · 2025
+65 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0862.423.436
- VAT number
- BE 0862.423.436
- Registered office
- Lennikse Baan 451, 1070 Anderlecht
- Names & denominations
- OCTAPHARMA BENELUX
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 December 2003
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten